Publicaciones (168) Publicaciones de MARÍA DE LOS ÁNGELES GOICOECHEA DIEZHANDINO

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Chronic Kidney Disease–Associated Pruritus and Quality of Life: Learning from Our Patients

    Journal of Clinical Medicine, Vol. 12, Núm. 13

  3. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis

    Nefrologia, Vol. 43, Núm. 1, pp. 6-47

  4. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)

    Clinical Kidney Journal, Vol. 16, Núm. 9, pp. 1384-1402

  5. Etiopathogenesis of chronic kidney disease-associated pruritus: putting the pieces of the puzzle together

    Nefrologia, Vol. 43, Núm. 1, pp. 48-62

  6. Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD

    Clinical journal of the American Society of Nephrology : CJASN, Vol. 18, Núm. 2, pp. 183-192

  7. Hemodiafiltration with endogenous reinfusion of the regenerated ultrafiltrate (HFR): Towards a convective, diffusive, and adsorptive dialysis

    Nefrologia, Vol. 43, Núm. 6, pp. 688-702

  8. Impact of preoperative exercise in not initially candidates to native arteriovenous fistulas

    Journal of Vascular Access, Vol. 24, Núm. 4, pp. 689-695

  9. Obesity, chronic kidney disease progression and the role of the adipokine C1q/TNF related protein-3

    Nefrologia, Vol. 43, Núm. 3, pp. 328-334

  10. Perception of Spanish nephrologists on an old unsolved problem: Pruritus associated with chronic kidney disease (CKD-aP)

    Nefrologia, Vol. 43, Núm. 1, pp. 102-110

  11. Peripheral arterial disease in hemodialysis patients 10 years later

    Nefrologia, Vol. 43, Núm. 3, pp. 302-308

  12. Prevalence and severity of pruritus in Spanish patients with chronic kidney disease and impact on quality of life: a cross-sectional study

    Clinical Kidney Journal

  13. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

    Kidney International, Vol. 103, Núm. 2, pp. 391-402